Fertility preservation with ovarian stimulation and time to treatment in women with stage II–III breast cancer receiving neoadjuvant therapy

Overview of attention for article published in Breast Cancer Research and Treatment, May 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#13 of 4,675)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (97th percentile)

Mentioned by

news: 52 news outlets

twitter: 1 X user

Citations

dimensions_citation: 50 Dimensions

Readers on

mendeley: 98 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 54 news stories from 52 outlets.

Genomic Health Release: New Analysis From German Study Group Prospective Trial Shows Minimal Distant Recurrence In Patients With Clinically High-Risk Breast Cancer And Low Oncotype DX Breast Recurrence Score?? Results Following Five Years Of Hormone Thera

Biospace, 12 Sep 2017

Additional large population-based study indicates not all young women under 40 years with node negative breast cancer have…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

NewsWest9, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

2 News, 11 Sep 2017

Information contained on this page is provided by an independent third-party content provider.

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Mississippi News Now , 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KUSI News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WFMJ, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

NewsOn6, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WRCB- TV, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

News Channel 6, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Kuam, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WMC Action News 5, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KHQ, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WBOC 16, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

ABC 7 News KSWO, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WTOC, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KTRE, 11 Sep 2017

Information contained on this page is provided by an independent third-party content provider.

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KAIT-TV, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

14 News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WMBF News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Cleveland 19, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WISTV, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KTEN, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WDAM - TV, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

NBC12, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KLTV, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WTOL, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WTVM, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

CBS8, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

South Carolina News Now, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

News 9, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KSLA News 12, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WAND 17, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

NBC Right Now KNDU 25, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Fox 14 News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KLKN-TV Eyewitness News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

48 WAFF, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KPLC 7 News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

News Channel, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WSFA , 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Wave 3 News, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WLOX, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WALB, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

KFVE The Home Team, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Hawaii News Now, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

WFLX Fox 29, 11 Sep 2017

SOURCE Genomic Health, Inc. New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Ticker Tech, 11 Sep 2017

REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Ariva, 11 Sep 2017

PR Newswire REDWOOD CITY, Calif., Sept. 11, 2017 REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc.

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Benzinga, 11 Sep 2017

New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Pettinga: Stock Market, 11 Sep 2017

REDWOOD CITY, Calif. Results from a first-of-its-kind analysis including over 6,000 patients younger than age 40 from the…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

NASDAQ, 11 Sep 2017

New SEER Registry Analysis Indicates Many Young Women Under 40 Years with Node-negative Breast Cancer Do Not Have Aggressive…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

PR Newswire, 11 Sep 2017

REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ --. (Nasdaq: ) today announced the presentation of new data that provide…

Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017

Bioportfolio, 11 Sep 2017

REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of…

New Analysis from German Study Group Prospective Trial Shows Minimal Distant Recurrence in Patients with Clinically High-Risk Breast Cancer and Low Oncotype DX Breast Recurrence Score® Results ...

Bioportfolio, 11 Sep 2017

Additional large population-based study indicates not all young women under 40 years with node negative breast cancer have…

Genomic Health Presents Data Demonstrating Importance Of Oncotype DX Breast Recurrence Score Test In Predicting Outcomes Across Patient Populations At

Biospace, 11 Sep 2017

REDWOOD CITY, Calif., Sept. 11, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of…